Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osmetech requests FDA emergency approval for swine flu test

This article was originally published in Clinica

Executive Summary

In a bid to allow the use of its respiratory pathogen test panel to diagnose swine flu, Osmetech has applied to the US FDA for emergency use authorisation (EUA). EUAs are used during public healthcare emergencies; a state of emergency was declared in the US on April 26. The Pasadena, California-based molecular diagnostics firm expects to launch the panel – designed to identify 18 bacterial and viral infections, including the influenza A H1N1 swine flu virus – in the next quarter, for research use only. It is now developing an extension to differentiate between the human and swine forms of the H1N1 virus. The panel, adapted from Qiagen's QIAplex-based respiratory viral test, runs on Osmetech's eSensor XT-8 system.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel